<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0182373</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-11077</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Gynecological tumors</subject><subj-group><subject>Cervical cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell processes</subject><subj-group><subject>Cell cycle and cell division</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Cloning</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell processes</subject><subj-group><subject>Cell cycle and cell division</subject><subj-group><subject>Mitosis</subject><subj-group><subject>Prometaphase</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Chromosome biology</subject><subj-group><subject>Mitosis</subject><subj-group><subject>Prometaphase</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Chemotherapeutic agents</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Oncology agents</subject><subj-group><subject>Chemotherapeutic agents</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell processes</subject><subj-group><subject>Cell death</subject><subj-group><subject>Apoptosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Database and informatics methods</subject><subj-group><subject>Biological databases</subject><subj-group><subject>Genomic databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Computational biology</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genomic databases</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genomic databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>DNA-binding proteins</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>CRISPR/Cas9-mediated knockout of <italic>c-REL</italic> in HeLa cells results in profound defects of the cell cycle</article-title>
<alt-title alt-title-type="running-head"><italic>c-REL</italic> deletion results in cell cycle defects</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Slotta</surname>
<given-names>Carsten</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Schlüter</surname>
<given-names>Thomas</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ruiz-Perera</surname>
<given-names>Lucia M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kadhim</surname>
<given-names>Hussamadin M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tertel</surname>
<given-names>Tobias</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Henkel</surname>
<given-names>Elena</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Hübner</surname>
<given-names>Wolfgang</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0524-662X</contrib-id>
<name name-style="western">
<surname>Greiner</surname>
<given-names>Johannes F. W.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Huser</surname>
<given-names>Thomas</given-names>
</name>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kaltschmidt</surname>
<given-names>Barbara</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Kaltschmidt</surname>
<given-names>Christian</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Cell Biology, University of Bielefeld, Bielefeld, Germany</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>AG Molecular Neurobiology, University of Bielefeld, Bielefeld, Germany</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Biomolecular Photonics, University of Bielefeld, Bielefeld, Germany</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Romano</surname>
<given-names>Maria Fiammetta</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Universita degli Studi di Napoli Federico II, ITALY</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">c.kaltschmidt@uni-bielefeld.de</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>2</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>8</issue>
<elocation-id>e0182373</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>7</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Slotta et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0182373"/>
<abstract>
<p>Cervical cancer is the fourth common cancer in women resulting worldwide in 266,000 deaths per year. Belonging to the carcinomas, new insights into cervical cancer biology may also have great implications for finding new treatment strategies for other kinds of epithelial cancers. Although the transcription factor NF-κB is known as a key player in tumor formation, the relevance of its particular subunits is still underestimated. Here, we applied CRISPR/Cas9n-mediated genome editing to successfully knockout the NF-κB subunit <italic>c-REL</italic> in HeLa Kyoto cells as a model system for cervical cancers. We successfully generated a homozygous deletion in the <italic>c-REL</italic> gene, which we validated using sequencing, qPCR, immunocytochemistry, western blot analysis, EMSA and analysis of off-target effects. On the functional level, we observed the deletion of <italic>c-REL</italic> to result in a significantly decreased cell proliferation in comparison to wildtype (wt) without affecting apoptosis. The impaired proliferative behavior of <italic>c-REL</italic><sup>-/-</sup> cells was accompanied by a strongly decreased amount of the H2B protein as well as a significant delay in the prometaphase of mitosis compared to <italic>c-REL</italic><sup>+/+</sup> HeLa Kyoto cells. <italic>c-REL</italic><sup>-/-</sup> cells further showed significantly decreased expression levels of <italic>c-REL</italic> target genes in comparison to wt. In accordance to our proliferation data, we observed the <italic>c-REL</italic> knockout to result in a significantly increased resistance against the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. In summary, our findings emphasize the importance of c-REL signaling in a cellular model of cervical cancer with direct clinical implications for the development of new treatment strategies.</p>
</abstract>
<funding-group>
<funding-statement>The authors received no specific funding for this work.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<page-count count="19"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Cervical cancer is an epithelial cancer, also called carcinoma, and the fourth common cancer in women worldwide with an estimated 5-year survival rate of 70% following diagnosis [<xref ref-type="bibr" rid="pone.0182373.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0182373.ref002">2</xref>]. Based on the degenerated cell type in the uterus, cervical cancer can be classified into squamous cell cancer and adenocarcinoma [<xref ref-type="bibr" rid="pone.0182373.ref001">1</xref>]. The most common reason for cervical cancer is an infection by the human papilloma virus (HPV), namely by HPV 16 and HPV 18 causing malignant transformations or carcinogenesis in 85% of the diagnosed cases [<xref ref-type="bibr" rid="pone.0182373.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0182373.ref004">4</xref>]. Treatment strategies of cervical cancer highly depend on the stage of progression and range from radiotherapy and surgery [<xref ref-type="bibr" rid="pone.0182373.ref005">5</xref>] to chemotherapy with cisplatin or 5-fluorouracil (5-FU) [<xref ref-type="bibr" rid="pone.0182373.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0182373.ref007">7</xref>].</p>
<p>Discovered in 1986 [<xref ref-type="bibr" rid="pone.0182373.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0182373.ref009">9</xref>], the transcription factor nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) has been shown to play a key role in various cellular processes as cell growth, differentiation, apoptosis, inflammation, learning and memory as well as immunity [<xref ref-type="bibr" rid="pone.0182373.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0182373.ref011">11</xref>]. Given the importance of NF-κB in these processes, deregulation of its signaling is directly associated to the formation of tumors and cancer progression [<xref ref-type="bibr" rid="pone.0182373.ref012">12</xref>–<xref ref-type="bibr" rid="pone.0182373.ref014">14</xref>], particularly regarding breast cancer [<xref ref-type="bibr" rid="pone.0182373.ref015">15</xref>] and cervical carcinomas [<xref ref-type="bibr" rid="pone.0182373.ref001">1</xref>]. In 2003, Nair and coworkers showed a constitutive activation of the NF-κB subunit p65 during human cervical cancer progression. Here, NF-κB p65 was demonstrated to be particularly activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix [<xref ref-type="bibr" rid="pone.0182373.ref016">16</xref>]. Next to NF-κB p65, the subunit c-REL was shown to possess a key role in tumor formation. Initial studies demonstrated severe B-cell lymphomas in chickens infected with avian reticuloendotheliosis comprising V-REL [<xref ref-type="bibr" rid="pone.0182373.ref017">17</xref>]. Expression of wildtype human <italic>c-REL</italic> in primary chicken spleen cell cultures was likewise shown to result in malignant transformation events [<xref ref-type="bibr" rid="pone.0182373.ref018">18</xref>], although respective mutations increasing the oncogenicity of the c-REL protein in the avian system were not observable in human cancers (reviewed in [<xref ref-type="bibr" rid="pone.0182373.ref019">19</xref>]). However, amplification of <italic>c-REL</italic> was observed in a broad range of human B-cell lymphomas [<xref ref-type="bibr" rid="pone.0182373.ref020">20</xref>, <xref ref-type="bibr" rid="pone.0182373.ref021">21</xref>]. In terms of human cervical cancer, Shehata and coworkers demonstrated a 6-fold slowed cell growth in cultivated cervical cancer cells by expression of the <italic>c-REL</italic> homolog Xrel3 from <italic>Xenopus laevi</italic> [<xref ref-type="bibr" rid="pone.0182373.ref022">22</xref>]. Accordingly, downregulation of <italic>c-REL</italic> by small interfering RNA was shown to result in reduced proliferation of human keratinocytes [<xref ref-type="bibr" rid="pone.0182373.ref023">23</xref>], directly correlating <italic>c-REL</italic> signaling to impaired cell cycle progression in a non-cancerous environment. Expression of the <italic>c-REL</italic> homolog Xrel3 in human cervical cancer cells was further shown to lead to anti- or pro-apoptotic effects during cisplatin-treatment in a concentration-dependent manner. These findings emphasize the importance of <italic>c-REL</italic>-signaling in resistance of cervical carcinoma to chemotherapeutic agents [<xref ref-type="bibr" rid="pone.0182373.ref024">24</xref>].</p>
<p>The present study further extends these promising findings by showing a profound overexpression of <italic>c-REL</italic> in cancers located in human ovary, cervix and endometrium using database mining. To investigate the role of <italic>c-REL</italic> in human cervical cancers in more detail, we applied CRISPR/Cas9n-mediated genome editing in a multiplex way to delete <italic>c-REL</italic> in HeLa Kyoto cells. Initially discovered as a part of adaptive immune system of bacteria and archaea [<xref ref-type="bibr" rid="pone.0182373.ref025">25</xref>], the clustered regularly interspaced short palindromic repeats (CRISPR) system has been developed to a state-of-the-art technique for editing the human genome [<xref ref-type="bibr" rid="pone.0182373.ref026">26</xref>, <xref ref-type="bibr" rid="pone.0182373.ref027">27</xref>]. Applications of the CRISPR/Cas9-system particularly include cancer modeling [<xref ref-type="bibr" rid="pone.0182373.ref028">28</xref>] or knockout studies using human cancer cell lines [<xref ref-type="bibr" rid="pone.0182373.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0182373.ref029">29</xref>]. In the present study, we applied a Cas9 nickase mutant (Cas9n) inducing single-strand breaks to minimize the possibility of off-target cleavage in turn increasing the specificity of genome editing [<xref ref-type="bibr" rid="pone.0182373.ref030">30</xref>].</p>
<p>Using the CRISPR/Cas9n approach, we successfully deleted the <italic>c-REL</italic> gene on chromosomes 2 of HeLa Kyoto cells (<italic>c-REL</italic><sup>-/-</sup>). In comparison to wildtype, <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells showed a significantly decreased proliferation accompanied by strongly reduced amounts of histone H2B, a delay in the prometaphase of mitosis and decreased expression levels of <italic>c-REL</italic> target genes. We further observed a significantly increased resistance against the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin in HeLa Kyoto cells with <italic>c-REL</italic> deletion compared to wildtype (wt). Our findings emphasize the importance of <italic>c-REL</italic> signaling in a cellular model of cervical cancer with direct clinical implications concerning the resistance of cervical carcinoma to chemotherapeutic agents.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Target design and cloning</title>
<p>The design of the sgRNAs was done using the CRISPR/Cas9n Target Online Predictor from University of Heidelberg (crispr.cos.uni-heidelberg.de). The gene sequence was taken from Ensembl Genome Browser (ensembl.org). Two nicking pairs were designed resulting in two double strand breaks creating a deletion. Nicking pairs were chosen according to the criteria described by Ran and coworkers [<xref ref-type="bibr" rid="pone.0182373.ref030">30</xref>]. All oligos designed were cloned into one vector essentially as described [<xref ref-type="bibr" rid="pone.0182373.ref031">31</xref>].</p>
</sec>
<sec id="sec004">
<title>Cell culture and transfection</title>
<p>HeLa Kyoto cells [<xref ref-type="bibr" rid="pone.0182373.ref032">32</xref>] were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma Aldrich, Taufkirchen, Germany) containing high glucose (25 mM), and sodium pyruvate (1 mM). This medium was supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) (VWR, Darmstadt, Germany), 2 mM L-glutamine (Sigma Aldrich), 100 U/ml Penicillin/Streptomycin (P/S) (Sigma Aldrich), and 0.5 mg/ml geneticin (G418) (Sigma Aldrich). Cells were cultivated at 37°C with 5% CO<sub>2</sub> at saturated humidity.</p>
<p>Transfection of HeLa Kyoto cells (3 x 10<sup>5</sup> cells / transfection) was performed by electroporation using Amaxa Cell Line Nucleofector Kit R (Lonza, Basel, Schweiz) according to the manufacturer’s protocol. 48 hours after transfection knockout generation was checked by genomic PCR and cells were used for limiting dilution to obtain clonal <italic>c-REL</italic> knockout cells.</p>
</sec>
<sec id="sec005">
<title>Genomic PCR and Native PAGE</title>
<p>For cell lysis, cells were harvested at 300 g for 5 min and resuspended in cell lysis buffer (0.1 μg/mL gelatine, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.45% NP40, 10 mM TRIS pH 8.3, 0.45% TWEEN 20). Proteinase K (20 mg/ml, Serva Electrophoresis, Heidelberg, Germany) was added followed by incubation of the cell lysate for at least 1 h at 55°C and 5 min at 95°C. 2 μL were used for PCR (<italic>c-REL</italic> primers: Fw <monospace>5´-TGCATTTTCATTTTCAGTGAATGGT-3´,</monospace> Rev <monospace>5´-ACCTGTGGAGATGACTGTGAAG-3´</monospace>). Resulting bands on agarose gels were extracted using NucleoSpin Gel and PCR Clean up Kit (Macherey Nagel) according to manufacturer’s guidelines and subsequently analyzed by sequencing.</p>
<p>For Native PAGE, DNA of the PCR product was denaturized and re-annealed (5 min at 95°C, -2°C/s from 95°C to 85°C and 0.1°C/s from 85°C to 25°C). PCR product was separated on a 10% native Polyacrylamide-gel for 2 h at 150 V. Gene Ruler DNA Ladder Mix (Thermo Fisher Scientific, Waltham, MA, USA) served as marker, gel was immersed in 0.05% ethidium bromide (Carl Roth GmbH, Karlsruhe, Germany) for 5 min prior to visualization.</p>
</sec>
<sec id="sec006">
<title>Quantitative real-time PCR</title>
<p>RNA isolation was done with NucleoSpin<sup>®</sup>RNA Kit (Macherey-Nagel) according to manufacturer’s guidelines. 500 ng RNA were used for cDNA synthesis. Quantitative real-time PCR (qPCR) was performed using SYBR Green Master Mix (Thermo Fisher Scientific). cDNA was diluted 1:50 and 2 μL/reaction were used as template. Primer sequences were <monospace>5´-CTCCTGACTGACTGACTGCG-3´</monospace> (Fw <italic>c-REL</italic> target deletion), <monospace>5´-TACGGGTTATACGCACCGGA-3´</monospace> (Rev <italic>c-REL</italic> target deletion), <monospace>5´-CCTGGAGCAGGCTATCAGTC-3´</monospace> (Fw <italic>RELA</italic>), <monospace>5´-CACTGTCACCTGGAAGCAGA-3´</monospace> (Rev <italic>RELA</italic>), <monospace>5´-ACATCAAGGAGAACGGCTTCG-3´</monospace> (Fw <italic>RELB</italic>), <monospace>5´-GACACTAGTCGGCCCAGG-3´</monospace> (Rev <italic>RELB</italic>), <monospace>5´-GCACCCTGACCTTGCCTATT-3´</monospace> (Fw <italic>NFKB1</italic>), <monospace>5´-GCTCTTTTTCCCGATCTCCCA-3´</monospace> (Rev NFKB1), <monospace>5´-CAACCCAGGTCTGGATGGTA-3´</monospace> (Fw <italic>NFKB2</italic>), <monospace>5´-CTGCTTAGGCTGTTCCACGA -3´</monospace> (Rev NFKB2), <monospace>5´-TGACAGTGAGCCCTGAAAGC-3´</monospace> (Fw <italic>IKBKE</italic>), <monospace>5´-CCGGATTTCCCACACTCTGA-3´</monospace> (Rev <italic>IKBKE</italic>), <monospace>5´-CGGAGACCCGGCTGGTATAA-3´</monospace> (Fw <italic>TBK1</italic>), <monospace>5´-ATCCACTGGACGAAGGAAGC-3´</monospace> (Rev <italic>TBK1</italic>), <monospace>5´-CTGAAAACGAACGGTGACGG-3´</monospace> (Fw <italic>A20</italic>), <monospace>5´-TCCAGTTGCCAGCGGAATTT-3´</monospace> (Rev <italic>A20</italic>), <monospace>5´-CAGGATAACGGAGGCTGGGATG-3´</monospace> (Fw <italic>BCL2</italic>), <monospace>5´-TTCACTTGTGGCCCAGATAGG -3´</monospace> (Rev <italic>BCL2</italic>), <monospace>5´-GCTTGGATGGCCACTTACCT-3´</monospace> (Fw <italic>BCL-XL</italic>), <monospace>5´-ACAAAAGTATCCCAGCCGCC-3´</monospace> (Rev <italic>BCL-XL</italic>), <monospace>5´-GCAAGTGGACATCAACGGGT-3´</monospace> (Fw <italic>TGFB1</italic>), <monospace>5´- TCCGTGGAGCTGAAGCAATA-3´</monospace> (Rev <italic>TGFB1</italic>), <monospace>5´-GTAGTGGAAAACCAGCAGCC-3´</monospace> (Fw <italic>MYC</italic>), <monospace>5´-AGAAATACGGCTGCACCGAG-3´</monospace> (Rev <italic>MYC</italic>), <monospace>5´-ATGGCAACGACTCCTTCTCG-3´</monospace> (Fw <italic>ICAM-1</italic>), <monospace>5´-GCCGGAAAGCTGTAGATGGT-3´</monospace> (Rev <italic>ICAM-1</italic>). Ct values were normalized to reference genes <italic>GAPDH</italic> (Fw <monospace>5´-CATGAGAAGTATGACAACAGCCT-3´,</monospace> Rev <monospace>5´-AGTCCTTCCACGATACCAAAGT-3´</monospace>), <italic>RPLP0</italic> (Fw <monospace>5´-TGGGCAAGAACACCATGATG-3´,</monospace> Rev <monospace>5´-AGTTTCTCCAGAGCTGGGTTGT-3´</monospace>) and <italic>eEF2</italic> (Fw <monospace>5´-AGGTCGGTTCTACGCCTTTG-3´, 5´-TTCCCACAAGGCACATCCTC-3´</monospace>).</p>
</sec>
<sec id="sec007">
<title>Western blotting</title>
<p>For analysis of RELA and A20, <italic>c-REL</italic><sup>-/-</sup> and <italic>c-REL</italic><sup>+/+</sup> cells were treated with human recombinant TNFα (10ng/ml, Calbiochem, Merck, Darmstadt, Germany) for 24h prior to protein isolation. Protein extracts were made using cell lysis buffer (0.01 M TRIS, 3 mM EDTA, 1% SDS) and equal amounts of protein were separated by SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked using PBS containing 0.05% Tween 20 and 5% milk powder and probed with primary antibodies (rabbit anti-c-REL (#4727), Cell Signaling Technology, Danvers, MA, USA); rabbit anti-p65 (#8242), Cell Signaling; mouse anti-A20 (sc-166692), Santa Cruz Biotechnology, Heidelberg, Germany) overnight at 4°C. Horseradish peroxidase-conjugated secondary antibodies were applied for 1h at room temperature and blots were subsequently developed using enhanced chemiluminescence.</p>
</sec>
<sec id="sec008">
<title>Electrophoretic mobility shift assay</title>
<p>Electrophoretic Mobility Shift Assay was performed using DIG Gel Shift Kit, 2nd generation (Deutschland Holding GmbH, Grenzach-Wyhlen, Germany) according to manufacturer’s guidelines. For <italic>c-REL</italic> probe sequence (5´-TCGAGGGCTCGGGCTTTCCATCTCTCGA-3´), <italic>c-REL</italic> binding site CGGGCTTTCC was assessed using the JASPAR Tool (jaspar.genereg.net). Protein isolation procedure and unspecific competitor sequence were applied as described by Tokunaga and coworkers [<xref ref-type="bibr" rid="pone.0182373.ref033">33</xref>]. PAGE was performed as described above.</p>
</sec>
<sec id="sec009">
<title>Immunocytochemistry and fluorescence imaging of H2B-mcherry</title>
<p>For immunostaining and imaging of H2B-mCherry cells were seeded and cultivated on coverslips. Fixation was done by adding 4% paraformaldehyde (PFA) for 10 min. After repetitive washing using phosphate-buffered saline (PBS), cells were either directly mounted with Mowiol/DABCO or carried over to immunostaining. For immunocytochemistry, cells were blocked and permeabilized using 0.02% PBST (PBS with Triton X-100) containing 5% goat serum for 30 min at RT. Primary antibody (rabbit anti-c-REL (#4727), Cell Signaling; mouse anti-CD54/ICAM MAB1379, Chemicon, Merck) was applied for 1 h at RT. After washing, cells were incubated with secondary antibody (goat anti-rabbit Alexa Fluor 647, Thermo Fisher Scientific) for 1 h at RT under exclusion of light. Finally, coverslips were mounted with Mowiol/DABCO. Imaging was done by confocal laser scanning microscopy (LSM 780, Carl Zeiss, Oberkochen, Germany) and image processing was done using Fiji) and Adobe Photoshop CS6 (Adobe Systems, San José, USA) or Corel Draw (Corel Corporation, Ottawa, Canada).</p>
</sec>
<sec id="sec010">
<title>Proliferation &amp; survival assay</title>
<p>Proliferation was analyzed with Orangu Cell Proliferation Assay Kit (Cell Guidance Systems, Cambridge, UK) used following the manufacturer’s protocol. Cells were counted with Cellometer Auto T4 Cell Viability Counter (Nexcelom, Lawrence, USA). For a calibrating curve 1000, 2500, 5000, 7500, 10000 and 15000 wildtype cells were seeded and incubated for 24 h at 37°C. For correct cell number determination after one day, one well of each condition was recounted.</p>
<p>For survival assay 5000 cells in 100 μl were seeded one day before treatment. Cells were incubated with chemotherapeutic agents cisplatin (CDDP) (P4394, Sigma Aldrich) and 5-Fluoro-2´-deoxyuridine (5-FUDR) (Sigma Aldrich) for 21 h and subsequently Orangu Cell Proliferation Assay Kit was applied.</p>
</sec>
<sec id="sec011">
<title>Flow cytometric analysis of the cell cycle, apoptosis and histone H2B-mCherry</title>
<p>DNA content measurement for analyzing cell cycle parameters was performed according to Kaltschmidt and colleagues [<xref ref-type="bibr" rid="pone.0182373.ref034">34</xref>] by harvesting 1 x 10<sup>6</sup> cells at 300 g for 5 min followed by fixation with 70% (v/v) ethanol. After centrifugation at 300 x g for 10 minutes, staining solution (PBS containing 1 mg/ml glucose (Carl Roth GmbH), 4´,6-diamidino-2-phenylindole (DAPI; 0.5 mg/ml; Sigma-Aldrich), and 100 Kunitz units RNaseA (Thermo Fisher Scientific) was applied for 60 min under exclusion of light.</p>
<p>For apoptosis measurement, 1 x 10<sup>6</sup> cells were labeled with Annexin V-PE (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. For analysis of H2B-mCherry, 1 x 10<sup>6</sup> <italic>c-REL</italic><sup>+/+</sup> and <italic>c-REL</italic><sup>-/-</sup> cells were harvested and directly applied for flow cytometric analysis without additional staining procedures.</p>
<p>DAPI or Annexin V-PE-labeled cells as well as unstained cells (H2B-mCherry) were analyzed using a Gallios<sup>™</sup> 10/3 flow cytometer (Beckman Coulter, Brea, CA, USA). Data analysis was performed using FlowJo Software (TreeStar, Olten, Switzerland), doublet discrimination for cell cycle analysis was assured by appropriate gating strategies.</p>
</sec>
<sec id="sec012">
<title>Live cell imaging</title>
<p>We imaged H2B-mCherry alpha-tubulin-eGFP expressing HeLa Kyoto c-REL+/+ and c-REL -/- cells in growth conditions at 37 degrees for more than 20 hours with a DeltaVision Elite imaging system (GE Healthcare). At 20x magnification (Olympus UPlanSApo 20x 0.75), we recorded on a CoolSNAP HQ2 (Photometrics, USA) CCD camera 15 different lateral positions with 3 axial position with 1μm spacing for each c-REL+/+ and c-REL-/- cells respectively every 10 minutes for each fluorescent emission channels (LED excitation source 461-489nm, 553-597nm and emission filtered at 501-549nm, 603-647nm respectively). A DIC image was recorded for reference at each timepoint. The fluorescent images were deconvolved with the appropriate OTF in SoftWoRx (version 6.1.3, GE Healthcare), analysed with Fiji and figures were prepared with Omero.</p>
</sec>
<sec id="sec013">
<title>Promoter analysis</title>
<p>Sequence of promoter regions (1500 bp downstream and 100 bp upstream to respective ATG, 5000 bp downstream for c-Myc promoter) of interest were taken from Eukaryotic Promoter Database (epd.vital-ti.ch) for <italic>Homo sapiens</italic>. Binding sites for gene of interest in chosen promoter sequence were looked up using JASPAR Tool (jaspar.genereg.net). A relative score threshold of 85% was used. <italic>RELA</italic> and <italic>c-REL</italic> binding sites were compared in promoter regions of selected target genes.</p>
</sec>
<sec id="sec014">
<title>Statistics</title>
<p>All statistical tests were performed with PrismGraph Pad 5 (GraphPad Software, La Jolla, USA). Statistical significance of qPCR results and fluorescence intensity quantification was analyzed using unpaired t-test. Welch correction was performed, if variances were significantly different. Data of proliferation and survival assays were shown to be not normally distributed (Shapiro-Wilk test) and analyzed using Kruskal-Wallis test with Dunn post-hoc test.</p>
</sec>
</sec>
<sec id="sec015" sec-type="results">
<title>Results</title>
<sec id="sec016">
<title><italic>c-REL</italic> is overexpressed in human cervical cancers</title>
<p>To assess the clinical implications of a <italic>c-REL</italic> knockout, we assessed levels of <italic>c-REL</italic> overexpression in human cancers by database mining using COSMIC [<xref ref-type="bibr" rid="pone.0182373.ref035">35</xref>]. We found <italic>c-REL</italic> to be profoundly overexpressed in human cancers, particularly within those located in human ovary, cervix and endometrium in comparison to oesophagus (<xref ref-type="fig" rid="pone.0182373.g001">Fig 1A</xref>, cancer.sanger.ac.uk; 02-14-2017 16:00; 02-21-2017 15:10). Due to their human cervix origin, we decided to apply HeLa Kyoto cells for the CRISPR/Cas9n-mediated <italic>c-REL</italic> knockout.</p>
<fig id="pone.0182373.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Assessment of <italic>c-REL</italic> overexpression in human cancers and target design of CRISPR/Cas9n-mediated <italic>c-REL</italic> knockout.</title>
<p><bold>A</bold>: Database mining revealed more profound overexpression of <bold><italic>c-</italic></bold><italic>REL</italic> in cancers from human ovary, cervix and endometrium compared to oesophagus ([<xref ref-type="bibr" rid="pone.0182373.ref035">35</xref>], sancer.sanger.ac.uk; 02-14-2017 16:00; 02-21-2017 15:10). <bold>B</bold>: Target design showing the proposed <bold><italic>c-</italic></bold><italic>REL</italic> knockout with an expected deletion around 450 bp targeting the intron 1-exon 2-boundary of the <bold><italic>c-</italic></bold><italic>REL</italic> gene. The design was done with the CRISPR/Cas9n Target Online Predictor from the University of Heidelberg [<xref ref-type="bibr" rid="pone.0182373.ref036">36</xref>], crispr.cos.uni-heidelberg.de) and the gene sequence was taken from Ensembl Genome Browser (ensembl.org).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec017">
<title>Successful knockout of <italic>c-REL</italic> in HeLa Kyoto cells using CRISPR/Cas9n</title>
<p>To generate a <italic>c-REL</italic> knockout in HeLa Kyoto cells, we designed a target deletion around 450 bp between intron 1 and exon 2 of chromosome 2 using the CRISPR/Cas9 Target Online Predictor tool (<xref ref-type="fig" rid="pone.0182373.g001">Fig 1B</xref>, [<xref ref-type="bibr" rid="pone.0182373.ref036">36</xref>], crispr.cos.uni-heidelberg.de). All designed oligonucleotides were cloned into an all-in-one vector according to Golden Gate Assembly method (mCRISPR, [<xref ref-type="bibr" rid="pone.0182373.ref031">31</xref>]) allowing easier generation of knockouts. Genomic PCR depicted a profound deletion of the <italic>c-REL</italic> gene in clonally grown HeLa Kyoto cells after transfection with the constructed CRISPR/Cas9 vector in comparison to untransfected HeLa Kyoto wt cells (<xref ref-type="fig" rid="pone.0182373.g002">Fig 2A</xref>). Sequencing analysis confirmed the knockout of around 433 bp in exon 2 of <italic>c-REL</italic> within the transfected HeLa Kyoto clone.</p>
<fig id="pone.0182373.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Successful validation of the <italic>c-REL</italic> knockout in HeLa Kyoto cells on DNA, mRNA and protein level.</title>
<p><bold>A:</bold> Genomic PCR depicting a profound deletion of the <italic>c-REL</italic> gene in the <italic>c-REL</italic> knockout clone (band at 300 bp) compared to the wt clone (band at 700 bp). <bold>B:</bold> Sequencing analysis confirmed the knockout in exon 2 of <italic>c-REL</italic>. <bold>C:</bold> qPCR with specific primers in targeted deletion of exon 2 showed no expression of <italic>c-REL</italic> on mRNA level in the <italic>c-REL</italic> knockout clone in comparison to wt. <bold>D:</bold> Western blot analysis validated the knockout of <italic>c-REL</italic> on protein level. <bold>E:</bold> Electrophoretic mobility shift assays (EMSA) showed DNA-binding of c-REL in HeLa Kyoto wt cells (arrow), which was not observable in the <italic>c-REL</italic> KO clone. <bold>F:</bold> Immunocytochemistry depicted a nearly complete loss of c-REL-protein in <italic>c-REL</italic> knockout clone compared to HeLa Kyoto wt cells.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec018">
<title>CRISPR/Cas9n-mediated <italic>c-REL</italic> knockout can be validated on mRNA and protein level</title>
<p>After initial analysis of the <italic>c-REL</italic> knockout on DNA level, we assessed the expression level of <italic>c-REL</italic> in the HeLa Kyoto knockout clone by qPCR with primers in the targeted deletion. In contrast to HeLa Kyoto wt cells showing a robust expression of <italic>c-REL</italic> on mRNA level, no expression was detectable in the <italic>c-REL</italic> knockout clone (<xref ref-type="fig" rid="pone.0182373.g002">Fig 2C</xref>). Notably, we analysed the top three predicted exonic off-targets and detected no significant signs of off-target effects in the <italic>c-REL</italic> kockout clone (<xref ref-type="supplementary-material" rid="pone.0182373.s001">S1 Fig</xref>).</p>
<p>In contrast to HeLa Kyoto wt cells, no c-REL protein was detectable in knockout cells by western blot analysis even after TNFα-dependent stimulation, confirming the knockout of <italic>c-REL</italic> on protein level (<xref ref-type="fig" rid="pone.0182373.g002">Fig 2D</xref>). Assessing a potential loss in functionality of the c-REL protein, we investigated DNA binding activity of c-REL using electrophoretic mobility shift assay (EMSA). <italic>c-REL</italic><sup><italic>-/-</italic></sup> cells showed no DNA-binding activity of c-REL (<xref ref-type="fig" rid="pone.0182373.g002">Fig 2E</xref>), whereas a clear shift was observable using HeLa Kyoto wt cells (<xref ref-type="fig" rid="pone.0182373.g002">Fig 2E</xref>, arrow). Immunocytochemistry further validated the <italic>c-REL</italic> knockout in the transfected HeLa Kyoto clone by showing a nearly complete loss of c-REL protein in comparison to HeLa Kyoto wt cells (<xref ref-type="fig" rid="pone.0182373.g002">Fig 2F</xref>).</p>
</sec>
<sec id="sec019">
<title>CRISPR/Cas9n-mediated deletion of <italic>c-REL</italic> results in a decreased proliferation of HeLa Kyoto cells without affecting apoptosis</title>
<p>We next analyzed potential effects of the <italic>c-REL</italic> knockout on proliferation and apoptosis of HeLa Kyoto cells. Using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems), proliferation of <italic>c-REL</italic> knockout and wt cells was assessed after 2 days. HeLa Kyoto <italic>c-REL</italic><sup>-/-</sup> cells showed a strongly increased population doubling time of 26.54 h compared to wt HeLa Kyoto cells displaying a population doubling time of 15.68 h (<xref ref-type="fig" rid="pone.0182373.g003">Fig 3A</xref>). This robustly decreased proliferative behavior of <italic>c-REL</italic> knockout cells was accompanied by a 0.81 fold decrease in the amount of mitotic cells compared to wildtype, as shown by cell cycle analysis using flow cytometric DNA content measurements (<xref ref-type="fig" rid="pone.0182373.g003">Fig 3B</xref>). However, we observed only slightly increased levels of Annexin V-positive apoptotic cells in <italic>c-REL</italic><sup>-/-</sup> cells compared to wt cells (<xref ref-type="fig" rid="pone.0182373.g003">Fig 3C</xref>), indicating the effect of the <italic>c-REL</italic> knockout on proliferation of HeLa Kyoto cells to be apoptosis-independent.</p>
<fig id="pone.0182373.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.g003</object-id>
<label>Fig 3</label>
<caption>
<title>CRISPR/Cas9-mediated deletion of <italic>c-REL</italic> results in a decreased proliferation of HeLa Kyoto cell accompanied by strongly reduced amounts of histone H2B.</title>
<p><bold>A:</bold> Cell number assessed by Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) set against cultivation time showed a strongly increased population doubling time of <italic>c-REL</italic> knockout cells compared to wt HeLa Kyoto cells. PDT: Population doubling time. <bold>B:</bold> Flow cytometric DNA content measurements of DAPI-stained <italic>c-REL</italic> knockout cells showed a decrease in the amount of mitotic cells in <italic>c-REL</italic> knockout cells compared to wildtype. <bold>C:</bold> Flow cytometric analysis of Annexin V-stained <italic>c-REL</italic><sup>-/-</sup> and wt HeLa Kyoto cells revealed only slightly increased amounts of apoptotic cells upon <italic>c</italic>-REL deletion in comparison to wt. <bold>D:</bold> Flow cytometric analysis of histone H2B-mCherry showed a strongly decreased amount of the H2B protein in 41.48% of <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells, which was observable in only 8.67% of HeLa Kyoto wt cells.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec020">
<title><italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells reveal strongly reduced levels of histone H2B accompanied by a significantly delayed prometaphase or complete arrest of the cell cycle</title>
<p>Assessing the reduced proliferative behavior of <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells in more detail, we analyzed the protein level of histone H2B, which is fused to mCherry in HeLa Kyoto cells [<xref ref-type="bibr" rid="pone.0182373.ref032">32</xref>]. Flow cytometric analysis of H2B-mCherry showed a strongly decreased amount of the H2B protein in 41.48% of <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells. On the contrary, we observed a reduced H2B protein level in only 8.67% of HeLa Kyoto wt cells (<xref ref-type="fig" rid="pone.0182373.g003">Fig 3D</xref>). Taking advantage of the H2B-mCherry and alpha-tubulin-EGFP fusion in HeLa Kyoto cells, we further visualized the different stages of mitosis in fixed cell samples and living cells. Fluorescence imaging of fixed cells revealed a significantly increased amount of <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells within the prometaphase compared to wt cells (<xref ref-type="fig" rid="pone.0182373.g004">Fig 4E</xref>). We investigated this effect of the <italic>c-REL</italic> deletion in more detail by live cell imaging. Here, <italic>c-REL</italic><sup>-/-</sup> cells showed a length of the prometaphase of 39.50 ± 9.96 min, which was significantly delayed in comparison to wt cells revealing a duration of the prometaphase of 18.42 ± 1.58 min (<xref ref-type="fig" rid="pone.0182373.g004">Fig 4A–4C</xref>, <xref ref-type="supplementary-material" rid="pone.0182373.s004">S1 Movie</xref>). In addition, we observed only 5.4% of wt cells but 25.7% of <italic>c-REL</italic><sup>-/-</sup> cells (n = 40) to arrest during mitosis without entry of the G2 phase of the cell cycle (<xref ref-type="fig" rid="pone.0182373.g004">Fig 4D</xref>, <xref ref-type="supplementary-material" rid="pone.0182373.s002">S2 Fig</xref>).</p>
<fig id="pone.0182373.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Knockout of <italic>c-REL</italic> leads to a significantly delayed prometaphase or even complete arrest of the cell cycle.</title>
<p><bold>A-B:</bold> Live cell imaging of <italic>c-REL</italic><sup>-/-</sup> and <italic>c-REL</italic><sup>+/+</sup> cells showed delayed duration of the prometaphase in <italic>c-REL</italic><sup>-/-</sup> (arrows) in comparison to wildtype. Mitosis was visualized by H2B-mCherry and alpha-tubulin-EGFP. <bold>C:</bold> Quantification of life cell imaging validated the significant delay of <italic>c-REL</italic><sup>-/-</sup> <italic>in</italic> length of the prometaphase (39.50 ± 9.96 min) in comparison to wt (18.42 ± 1.58 min) (n = 20). <bold>D:</bold> Exemplary images of <italic>c-REL</italic><sup>-/-</sup> cells arresting during mitosis without entry of the G2 phase of the cell cycle. <bold>E:</bold> Fluorescence imaging of H2B-mCherry in fixed cells displayed a significantly increased amount of <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells within the prometaphase compared to wt cells. (&gt;1000 cells quantified per genotype, n = 3). Scale bar: 25 μm.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.g004" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec021">
<title><italic>c-REL</italic> knockout leads to significantly decreased expression levels of NF-κB family members and cell cycle-associated <italic>c-REL</italic> target genes</title>
<p>Analyzing effects of the <italic>c-REL</italic> knockout in HeLa Kyoto cells on other NF-κB family members, we assessed respective gene expression levels by qPCR. <italic>c-REL</italic> knockout cells revealed significantly decreased mRNA levels of <italic>RELA</italic>, <italic>NFKB1 (p50)</italic>, <italic>NFKB2</italic> (<italic>p52)</italic>, IκB-Kinase ε (<italic>IKBKE</italic>) and TANK-binding kinase 1 (<italic>TBK1</italic>) compared to wildtype cells (<xref ref-type="fig" rid="pone.0182373.g005">Fig 5A</xref>). On the contrary, expression levels of <italic>RELB</italic> were not significantly affected in the <italic>c-REL</italic> knockout clone (<xref ref-type="fig" rid="pone.0182373.g005">Fig 5A</xref>).</p>
<fig id="pone.0182373.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.g005</object-id>
<label>Fig 5</label>
<caption>
<title><italic>c-REL</italic> knockout leads to significantly decreased expression levels of NF-κB family member and cell cycle-associated genes.</title>
<p><bold>A:</bold> qPCR analysis showing significantly decreased mRNA levels of NF-κB family members <italic>RELA</italic>, <italic>NFKB1 (p50)</italic>, <italic>NFKB2</italic> (<italic>p52)</italic>, <italic>IKBKE</italic> and <italic>TBK1</italic> in <italic>c-REL</italic> knockout cells compared to wildtype cells. <bold>B-C:</bold> Expression levels of cell cycle-related <italic>c-REL</italic> target genes <italic>A20</italic>, <italic>BCL2</italic>, <italic>BCL-XL</italic> and <italic>TGFB1</italic> and <italic>c-REL</italic> target genes <italic>MYC</italic> and <italic>ICAM-1</italic> were significantly decreased in <italic>c-REL</italic> knockout cells in comparison to HeLa Kyoto wildtype cells. <bold>D:</bold> Western blot analysis validated the reduced expression levels of RELA and A20 in <italic>c-REL</italic><sup>-/-</sup> cells in comparison to wt on protein level. WB were performed after TNFα-dependent stimulation of <italic>c-REL</italic><sup>-/-</sup> and <italic>c-REL</italic><sup>+/+</sup> cells. <bold>E:</bold> Immunocytochemistry revealed a strongly decreased protein amount of ICAM in <italic>c-REL</italic><sup>-/-</sup> cells in comparison to wt.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.g005" xlink:type="simple"/>
</fig>
<p>In accordance to the observed decrease in proliferation and in <italic>c-REL</italic> knockout cells, we further observed significantly decreased mRNA levels in cell cycle-related <italic>c-REL</italic> target genes. In particular, expression levels of A20 (<italic>TNFAIP3</italic>), B-cell lymphoma 2 (<italic>BCL2</italic>), B-cell lymphoma-extra large (<italic>BCLXL</italic>, <italic>BCL2L1</italic>) and transforming growth factor beta 1 (<italic>TGFB1</italic>) were found to be significantly decreased in comparison to HeLa Kyoto wildtype cells (<xref ref-type="fig" rid="pone.0182373.g005">Fig 5B</xref>). In addition, expression levels of the <italic>c-REL</italic> target genes <italic>MYC</italic> and Intercellular Adhesion Molecule 1 (<italic>ICAM-1</italic>) were likewise significantly decreased compared to wildtype HeLa Kyoto cells (<xref ref-type="fig" rid="pone.0182373.g005">Fig 5C</xref>).</p>
<p>Promoter analysis was further performed using the JASPAR Tool (jaspar.genereg.net) to validate the analyzed genes to be direct <italic>c-REL</italic> target genes. Binding sites for <italic>c-REL</italic> and <italic>RELA</italic> were analyzed in each promoter region and their presence confirmed <italic>IKBKE</italic>, <italic>TBK1</italic>, <italic>A20</italic>, <italic>BCL2</italic>, <italic>BCL-XL</italic>, <italic>TGFB1</italic>, <italic>MYC</italic> and <italic>ICAM-1</italic> to be direct <italic>c-REL</italic> target genes (<xref ref-type="supplementary-material" rid="pone.0182373.s003">S3 Fig</xref>).</p>
<p>To validate the decreased expression levels of <italic>c-REL</italic> target genes in <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells on protein level, we performed western blot analysis and immunocytochemistry. Western blot analysis revealed reduced amounts of RELA and A20 protein in <italic>c-REL</italic><sup>-/-</sup> cells in comparison to wt (<xref ref-type="fig" rid="pone.0182373.g005">Fig 5D</xref>). We further observed a nearly complete loss of ICAM protein in <italic>c-REL</italic><sup>-/-</sup> cells by immunocytochemistry, while HeLa Kyoto wt cells showed an unchanged amount of ICAM protein (<xref ref-type="fig" rid="pone.0182373.g005">Fig 5E</xref>).</p>
</sec>
<sec id="sec022">
<title>HeLa Kyoto cells with <italic>c-REL</italic> deletion show a significantly increased resistance against chemotherapeutic agents</title>
<p>With regards to the assessed overexpression of <italic>c-REL</italic> in human cancers (<xref ref-type="fig" rid="pone.0182373.g001">Fig 1A</xref>), potential clinical implications of the <italic>c-REL</italic> knockout were assessed by determining cell survival upon exposure to the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. Here, treatment with increasing concentration of 0.45–100 μM 5-FUDR for 21 h led to cell death of both <italic>c-REL</italic><sup><italic>-/-</italic></sup> and wildtype cells (<xref ref-type="fig" rid="pone.0182373.g006">Fig 6A</xref>).</p>
<fig id="pone.0182373.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Significantly increased resistance against chemotherapeutic agents in HeLa Kyoto cells with <italic>c-REL</italic> deletion.</title>
<p><bold>A:</bold> Although both HeLa Kyoto wildtype and <italic>c-REL</italic> knockout cells showed cell death after treatment with 5-Fluoro-2’-deoxyuridine, the <italic>c-REL</italic> knockout clone showed significantly elevated cell numbers in comparison to wildtype cells. Cells were exposed to chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) after 2 h of incubation. Cell number of untreated cells were set to 1 and used for comparison. <bold>B:</bold> Although cisplatin-treatment of 1–4 μM led to cell death of wildtype cells, survival of the <italic>c-REL</italic> knockout clone was significantly increased even in comparison to untreated control. Increasing concentrations of cisplatin (10–100 μM) affected survival of <italic>c-REL</italic> knockout cells, but cell numbers were still significantly elevated compared to wildtype. Cells were exposed to chemotherapeutic agents for 21 h, cell numbers were assessed using Orangu Cell Proliferation Assay Kit (Cell Guidance Systems) after 2 h of incubation. Cell number of untreated cells were set to 1 and used for comparison (n = 8).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.g006" xlink:type="simple"/>
</fig>
<p>However, 5-FUDR-treated <italic>c-REL</italic> knockout clone showed significantly increased cell numbers in comparison to wildtype cells, indicating a profoundly increased resistance against 5-FUDR (<xref ref-type="fig" rid="pone.0182373.g006">Fig 6A</xref>). We likewise observed this effect after treatment of HeLa Kyoto wildtype and knockout cells with cisplatin. While cisplatin-treatment of 0.45–4.5 μM led to cell death of wildtype cells, assessed cell numbers of the <italic>c-REL</italic> knockout clone were significantly increased even in comparison to untreated control (<xref ref-type="fig" rid="pone.0182373.g006">Fig 6B</xref>). Although exposure to increasing concentrations of cisplatin (10–100 μM) also resulted in cell death of <italic>c-REL</italic> knockout cells, cell number were still found to be significantly increased compared to wildtype, validating a robust resistance against cisplatin (<xref ref-type="fig" rid="pone.0182373.g006">Fig 6B</xref>).</p>
</sec>
</sec>
<sec id="sec023" sec-type="conclusions">
<title>Discussion</title>
<p>The present study shows a successful CRISPR/Cas9n-mediated knockout of the NF-κB subunit <italic>c-REL</italic> in HeLa Kyoto cells. HeLa cells are one of the most frequently used model systems for epithelial and in particular cervical cancers [<xref ref-type="bibr" rid="pone.0182373.ref037">37</xref>–<xref ref-type="bibr" rid="pone.0182373.ref039">39</xref>]. Here, we observed a significantly decreased proliferation of <italic>c-REL</italic><sup>-/-</sup> cells accompanied by a significant decline in expression levels of NF-κB target genes in comparison to wt cells. HeLa Kyoto cells with <italic>c-REL</italic> deletion further revealed a significantly increased resistance against the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. These are commonly used as the trademarked chemotherapeutics Platinol<sup>®</sup> and FUDR<sup>®</sup> in the clinic.</p>
<p>With NF-κB being involved in many cellular processes [<xref ref-type="bibr" rid="pone.0182373.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0182373.ref011">11</xref>], a broad range of genes were described to be direct targets of NF-κB, including cytokines, chemokines, cell adhesion molecules, cell surface receptors, regulators of apoptosis and growth factors [<xref ref-type="bibr" rid="pone.0182373.ref040">40</xref>]. Interestingly, particular subunits of NF-κB were only rarely directly linked to specific target genes. In the present study, <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells showed significantly decreased expression levels of NF-κB family members <italic>RELA</italic>, <italic>NFKB1</italic>, <italic>NFKB2</italic> as well as <italic>IKBKE</italic> and <italic>TBK1</italic>. We also observed several <italic>c-REL</italic> binding sites in the promoter region of the <italic>TBK1</italic> and <italic>IKBKE</italic> gene, suggesting <italic>TBK1</italic> and <italic>IKBKE</italic> as direct <italic>c-REL</italic> target genes. In addition to their role in phosphorylating NF-κB p65 [<xref ref-type="bibr" rid="pone.0182373.ref041">41</xref>], TBK1 and IKBKE were in turn described to directly phosphorylate the C-terminal domain of the c-REL protein resulting in its nuclear accumulation [<xref ref-type="bibr" rid="pone.0182373.ref042">42</xref>]. Extending these promising findings, we suggest a positive feedback loop by <italic>c-REL</italic>-mediated expression of <italic>TBK1</italic> and IKBKE in turn leading to a pronounced activation of <italic>c-REL</italic>. Being also closely linked to the pathogenesis of breast cancer by promoting activation of NF-κB [<xref ref-type="bibr" rid="pone.0182373.ref043">43</xref>], targeting <italic>IKBKE</italic> may be an interesting future perspective for developing new treatment strategies against cervical cancer. Next to <italic>TBK1</italic> and <italic>IKBKE</italic>, <italic>c-REL</italic> knockout was observed to be sufficient to downregulate the expression of <italic>MYC</italic> in growing HeLa cells by more than 50% with the relative <italic>MYC</italic> expression being highly elevated in comparison to other target genes. Accordingly, Grumont and coworkers showed an impaired expression of <italic>MYC</italic> in stage III thymocytes with a <italic>RELA</italic>/<italic>c-REL</italic> double knockout [<xref ref-type="bibr" rid="pone.0182373.ref044">44</xref>]. We also demonstrated the presence of three <italic>c-REL</italic> binding sites in the downstream region of the <italic>MYC</italic> promoter, further validating <italic>MYC</italic> as a direct target gene of <italic>c-REL</italic>.</p>
<p>In comparison to wildtype, <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells further revealed a significantly decreased expression of <italic>BCL-2</italic>, <italic>BCL-XL</italic> and <italic>A20</italic>, which are commonly known as anti-apoptotic genes [<xref ref-type="bibr" rid="pone.0182373.ref045">45</xref>, <xref ref-type="bibr" rid="pone.0182373.ref046">46</xref>]. In accordance to our promoter analysis depicting <italic>c-REL</italic>-binding sites, <italic>BCL-XL</italic> and <italic>BCL2</italic> were described to be direct <italic>c-REL</italic> target genes [<xref ref-type="bibr" rid="pone.0182373.ref047">47</xref>, <xref ref-type="bibr" rid="pone.0182373.ref048">48</xref>]. Expression of <italic>TGFB1</italic>, already known as direct target of <italic>c-REL</italic> [<xref ref-type="bibr" rid="pone.0182373.ref049">49</xref>] and a common inducer of cell proliferation [<xref ref-type="bibr" rid="pone.0182373.ref050">50</xref>], was also significantly reduced in <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells. On functional level, we observed the <italic>c-REL</italic> knockout to result in a significantly reduced proliferation, which we suggest to be at least in part mediated by the depicted decline in pro-proliferative target gene expression. In consistence with these findings, knockdown of the <italic>c-REL</italic> target gene <italic>IKBKE</italic> in HeLa cells was also shown to result in a suppression of proliferation [<xref ref-type="bibr" rid="pone.0182373.ref051">51</xref>]. In human keratinocytes, small interfering RNA-mediated knockdown of c-REL was reported to directly affect cell cycle progression by cell cycle delay of the G2/M phase [<xref ref-type="bibr" rid="pone.0182373.ref023">23</xref>]. The present study further extended these findings by showing the CRISPR-Cas9n-mediated knockout of <italic>c-REL</italic> to result in a robustly delayed prometaphase of mitosis accompanied by strongly reduced levels of histone H2B protein. In addition, we observed a novel linkage between the decreased amount of histone H2B protein and the prolonged prometaphase in <italic>c-REL</italic><sup>-/-</sup> cells. In mice, silencing of c-Rel by siRNA was shown to lead to a reduction of mitosis in a B cell tumor cell line [<xref ref-type="bibr" rid="pone.0182373.ref052">52</xref>]. Grumont and coworkers likewise demonstrated a cell cycle arrest in B-cells of <italic>c-Rel</italic><sup><italic>-/-</italic></sup> mice [<xref ref-type="bibr" rid="pone.0182373.ref053">53</xref>]. Our present findings for the first time transfer these promising data to the human cancerous systems and provide deeper insights into the biology of cervical cancers in relation to <italic>c-REL</italic>-signaling. In this regard, we were also able to observe significantly reduced expression levels of <italic>ICAM1</italic> in <italic>c-REL</italic><sup>-/-</sup> HeLa Kyoto cells. Downregulation of this adhesion molecule was described to result in a suppression of human breast cancer cell invasion with the level of expression being directly correlated to their metastatic potential [<xref ref-type="bibr" rid="pone.0182373.ref054">54</xref>]. Accordingly, inhibition of MYC protein family members have been shown to induce regression of lung cancer in mice [<xref ref-type="bibr" rid="pone.0182373.ref055">55</xref>], suggesting the downregulation of <italic>MYC</italic> observed here likewise to be linked to the reduced proliferation of <italic>c-REL</italic><sup>-/-</sup> cells.</p>
<p>The NF-κB subunit <italic>c-REL</italic> is also directly linked to cancer development and progression. In 1999, Krappmann and colleagues described a constitutive NF-κB-activity with NF-κB-complexes containing RELA and c-REL in malignant cells derived from Hodgkin’s disease [<xref ref-type="bibr" rid="pone.0182373.ref056">56</xref>]. Whereas <italic>c-REL</italic> was currently discussed as being mutated in hematopoietic and lymphoid tumors [<xref ref-type="bibr" rid="pone.0182373.ref057">57</xref>], a high throughput database analysis performed in the present study including 3397 hematopoietic and lymphoid tumors detected mutations in only a few samples [<xref ref-type="bibr" rid="pone.0182373.ref035">35</xref>, <xref ref-type="bibr" rid="pone.0182373.ref058">58</xref>]. In 2004, Futreal and coworkers described a ‘census’ of human cancers indicating mutations in &gt;1% of genes of the human genome to contribute to cancer, although genes showing solely altered expression levels were not included in this initial ‘census’ [<xref ref-type="bibr" rid="pone.0182373.ref059">59</xref>]. Here, we applied database mining using the COSMIC database [<xref ref-type="bibr" rid="pone.0182373.ref035">35</xref>] and observed profound overexpression of <italic>c-REL</italic> in various human tumors (<xref ref-type="table" rid="pone.0182373.t001">Table 1</xref>), which is in accordance to the observed amplification of <italic>c-REL</italic> in human B-cell lymphomas [<xref ref-type="bibr" rid="pone.0182373.ref020">20</xref>, <xref ref-type="bibr" rid="pone.0182373.ref021">21</xref>]. Likewise in line with previous studies, <italic>c-REL</italic> can be considered as one of the most oncogenic members of the NF-κB family, in fowl reticuloendotheliosis virus also contains mutated oncogenic <italic>v-Rel</italic> [<xref ref-type="bibr" rid="pone.0182373.ref018">18</xref>, <xref ref-type="bibr" rid="pone.0182373.ref019">19</xref>, <xref ref-type="bibr" rid="pone.0182373.ref052">52</xref>, <xref ref-type="bibr" rid="pone.0182373.ref060">60</xref>].</p>
<table-wrap id="pone.0182373.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0182373.t001</object-id>
<label>Table 1</label> <caption><title>Overexpression of <italic>REL</italic> in human cancers.</title></caption>
<alternatives>
<graphic id="pone.0182373.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">tissue type</th>
<th align="center">% of <italic>REL</italic> overexpression</th>
<th align="center">no. tested</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Ovary</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">7.52</td>
<td align="center" style="background-color:#C0C0C0">266</td>
</tr>
<tr>
<td align="left"><bold>Lung</bold></td>
<td align="char" char=".">7.26</td>
<td align="center">1019</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Urinary tract</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">7.11</td>
<td align="center" style="background-color:#C0C0C0">408</td>
</tr>
<tr>
<td align="left"><bold>Endometrium</bold></td>
<td align="char" char=".">6.81</td>
<td align="center">602</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Pancreas</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">6.7</td>
<td align="center" style="background-color:#C0C0C0">179</td>
</tr>
<tr>
<td align="left"><bold>Haematopoietic and lymphoid</bold></td>
<td align="char" char=".">6.33</td>
<td align="center">221</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Soft tissue</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">6.08</td>
<td align="center" style="background-color:#C0C0C0">263</td>
</tr>
<tr>
<td align="left"><bold>Cervix</bold></td>
<td align="char" char=".">5.86</td>
<td align="center">307</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Upper aerodigestive tract</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">5.75</td>
<td align="center" style="background-color:#C0C0C0">522</td>
</tr>
<tr>
<td align="left"><bold>Kidney</bold></td>
<td align="char" char=".">5.5</td>
<td align="center">600</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Thyroid</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">5.46</td>
<td align="center" style="background-color:#C0C0C0">513</td>
</tr>
<tr>
<td align="left"><bold>Large intestine</bold></td>
<td align="char" char=".">4.92</td>
<td align="center">610</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Stomach</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">4.91</td>
<td align="center" style="background-color:#C0C0C0">285</td>
</tr>
<tr>
<td align="left"><bold>Liver</bold></td>
<td align="char" char=".">4.83</td>
<td align="center">373</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>CNS</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">4.73</td>
<td align="center" style="background-color:#C0C0C0">697</td>
</tr>
<tr>
<td align="left"><bold>Prostate</bold></td>
<td align="char" char=".">4.62</td>
<td align="center">498</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Breast</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">3.71</td>
<td align="center" style="background-color:#C0C0C0">1104</td>
</tr>
<tr>
<td align="left"><bold>Skin</bold></td>
<td align="char" char=".">3.59</td>
<td align="center">473</td>
</tr>
<tr>
<td align="left" style="background-color:#C0C0C0"><bold>Oesophagus</bold></td>
<td align="char" char="." style="background-color:#C0C0C0">3.2</td>
<td align="center" style="background-color:#C0C0C0">125</td>
</tr>
<tr>
<td align="left"><bold>Adrenal gland</bold></td>
<td align="char" char=".">2.53</td>
<td align="center">79</td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>In the present study, knockout of <italic>c-REL</italic> in a cellular model of cervical carcinoma resulted in a significantly increased resistance against the chemotherapeutic agents 5-FUDR and cisplatin. Due to direct interaction of cisplatin and 5-fluorouracil with the DNA, highly proliferating cells are exposed to DNA damage resulting in cell-cycle arrest and cell death [<xref ref-type="bibr" rid="pone.0182373.ref061">61</xref>, <xref ref-type="bibr" rid="pone.0182373.ref062">62</xref>]. Thus, we suggest the reduced proliferation of HeLa <italic>c-REL</italic><sup>-/-</sup> cells to account for the observed increase in resistance against cisplatin and 5-FUDR. Although activation of NF-κB was also described to lead to a decreased sensitivity of cancer cells against chemotherapeutic treatment [<xref ref-type="bibr" rid="pone.0182373.ref063">63</xref>, <xref ref-type="bibr" rid="pone.0182373.ref064">64</xref>], our present findings propose a subunit specificity of NF-κB in terms of chemoresistance. While a knockout of <italic>c-REL</italic> promoted survival of HeLa cells to chemotherapy, expression of the <italic>c-REL</italic> homolog <italic>Xenopus</italic> Xrel3 in cervical cancer cells treated with 5 μM cisplatin was shown to result in increased apoptosis [<xref ref-type="bibr" rid="pone.0182373.ref024">24</xref>].</p>
<p>In summary, our findings emphasize the importance of <italic>c-REL</italic>-signaling in a cellular model of cervical cancer particularly in terms of proliferation and resistance to chemotherapeutic agents. Considering the proposed NF-κB-subunit specificity of chemoresistance, we provide deeper insights into cervical cancer biology with direct clinical implications for the development of new treatment strategies.</p>
</sec>
<sec id="sec024">
<title>Supporting information</title>
<supplementary-material id="pone.0182373.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>PAGE-analysis of top three predicted exonic off-targets revealed no signs of off-target effects in the <italic>c-REL</italic> knockout clone.</title>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182373.s002" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.s002" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Live cell imaging showing <italic>c-REL</italic><sup>-/-</sup> cells, which arrested during mitosis without entry of the G2 phase of the cell cycle.</title>
<p>Scale bar: 25 μm.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182373.s003" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.s003" xlink:type="simple">
<label>S3 Fig</label>
<caption>
<title>Promoter analysis using the JASPAR Tool (jaspar.genereg.net) validated <italic>IKBKE</italic>, <italic>TBK1</italic>, <italic>A20</italic>, <italic>BCL2</italic>, <italic>BCL-XL</italic>, <italic>TGFB1</italic>, <italic>MYC</italic> and <italic>ICAM</italic>-1 to be direct <italic>c-REL</italic> target genes.</title>
<p><italic>c-REL</italic> binding site is shown in magenta, <italic>RELA</italic> binding site is depicted in cyan and common binding sites are shown in purple.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0182373.s004" mimetype="video/mp4" position="float" xlink:href="info:doi/10.1371/journal.pone.0182373.s004" xlink:type="simple">
<label>S1 Movie</label>
<caption>
<title>Live cell imaging of <italic>c-REL</italic><sup>-/-</sup> and <italic>c-REL</italic><sup>+/+</sup> cells showed delayed duration of the prometaphase in <italic>c-REL</italic><sup>-/-</sup> in comparison to wildtype.</title>
<p>Mitosis was visualized by H2B-mCherry and alpha-tubulin-EGFP.</p>
<p>(MP4)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The excellent technical help of Angela Kralemann-Köhler is gratefully acknowledged.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0182373.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shehata</surname> <given-names>MF</given-names></name>. <article-title>Rel/Nuclear factor-kappa B apoptosis pathways in human cervical cancer cells</article-title>. <source>Cancer cell international</source>. <year>2005</year>;<volume>5</volume>(<issue>1</issue>):<fpage>10</fpage>. Epub 2005/04/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1475-2867-5-10" xlink:type="simple">10.1186/1475-2867-5-10</ext-link></comment> <object-id pub-id-type="pmid">15857509</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref002"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Stewart BW, Wild CP, (Editors). World Cancer Report 2014. World Health Organization; 2014.</mixed-citation></ref>
<ref id="pone.0182373.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schiffman</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Castle</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Jeronimo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Rodriguez</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Wacholder</surname> <given-names>S</given-names></name>. <article-title>Human papillomavirus and cervical cancer</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>370</volume>(<issue>9590</issue>):<fpage>890</fpage>–<lpage>907</lpage>. Epub 2007/09/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(07)61416-0" xlink:type="simple">10.1016/S0140-6736(07)61416-0</ext-link></comment> <object-id pub-id-type="pmid">17826171</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garland</surname> <given-names>SM</given-names></name>. <article-title>Human papillomavirus update with a particular focus on cervical disease</article-title>. <source>Pathology</source>. <year>2002</year>;<volume>34</volume>(<issue>3</issue>):<fpage>213</fpage>–<lpage>24</lpage>. Epub 2002/07/12. <object-id pub-id-type="pmid">12109780</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>O'Connell</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lew</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Demers</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lotocki</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities</article-title>. <source>Cancer epidemiology</source>. <year>2015</year>;<volume>39</volume>(<issue>4</issue>):<fpage>600</fpage>–<lpage>11</lpage>. Epub 2015/05/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.canep.2015.04.009" xlink:type="simple">10.1016/j.canep.2015.04.009</ext-link></comment> <object-id pub-id-type="pmid">26004990</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lorusso</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Petrelli</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Coinu</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Raspagliesi</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Barni</surname> <given-names>S</given-names></name>. <article-title>A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer</article-title>. <source>Gynecologic oncology</source>. <year>2014</year>;<volume>133</volume>(<issue>1</issue>):<fpage>117</fpage>–<lpage>23</lpage>. Epub 2014/02/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ygyno.2014.01.042" xlink:type="simple">10.1016/j.ygyno.2014.01.042</ext-link></comment> <object-id pub-id-type="pmid">24486604</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nishiyama</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Park</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Okamoto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hanaoka</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takano</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves</article-title>. <source>Clinical cancer research: an official journal of the American Association for Cancer Research</source>. <year>1999</year>;<volume>5</volume>(<issue>9</issue>):<fpage>2620</fpage>–<lpage>8</lpage>. Epub 1999/09/28.</mixed-citation></ref>
<ref id="pone.0182373.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sen</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Baltimore</surname> <given-names>D</given-names></name>. <article-title>Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism</article-title>. <source>Cell</source>. <year>1986</year>;<volume>47</volume>(<issue>6</issue>):<fpage>921</fpage>–<lpage>8</lpage>. Epub 1986/12/26. <object-id pub-id-type="pmid">3096580</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sen</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Baltimore</surname> <given-names>D</given-names></name>. <article-title>Multiple nuclear factors interact with the immunoglobulin enhancer sequences</article-title>. <source>Cell</source>. <year>1986</year>;<volume>46</volume>(<issue>5</issue>):<fpage>705</fpage>–<lpage>16</lpage>. Epub 1986/08/29. <object-id pub-id-type="pmid">3091258</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaltschmidt</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kaltschmidt</surname> <given-names>C</given-names></name>. <article-title>NF-kappaB in the nervous system</article-title>. <source>Cold Spring Harbor perspectives in biology</source>. <year>2009</year>;<volume>1</volume>(<issue>3</issue>):<fpage>a001271</fpage>. Epub 2010/01/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/cshperspect.a001271" xlink:type="simple">10.1101/cshperspect.a001271</ext-link></comment> <object-id pub-id-type="pmid">20066105</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perkins</surname> <given-names>ND</given-names></name>. <article-title>Integrating cell-signalling pathways with NF-kappaB and IKK function</article-title>. <source>Nature reviews Molecular cell biology</source>. <year>2007</year>;<volume>8</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>62</lpage>. Epub 2006/12/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrm2083" xlink:type="simple">10.1038/nrm2083</ext-link></comment> <object-id pub-id-type="pmid">17183360</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xia</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Shen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Verma</surname> <given-names>IM</given-names></name>. <article-title>NF-kappaB, an active player in human cancers</article-title>. <source>Cancer immunology research</source>. <year>2014</year>;<volume>2</volume>(<issue>9</issue>):<fpage>823</fpage>–<lpage>30</lpage>. Epub 2014/09/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/2326-6066.CIR-14-0112" xlink:type="simple">10.1158/2326-6066.CIR-14-0112</ext-link></comment> <object-id pub-id-type="pmid">25187272</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Withoff</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Verma</surname> <given-names>IM</given-names></name>. <article-title>Inflammation-associated cancer: NF-kappaB is the lynchpin</article-title>. <source>Trends in immunology</source>. <year>2005</year>;<volume>26</volume>(<issue>6</issue>):<fpage>318</fpage>–<lpage>25</lpage>. Epub 2005/06/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.it.2005.04.003" xlink:type="simple">10.1016/j.it.2005.04.003</ext-link></comment> <object-id pub-id-type="pmid">15922948</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ben-Neriah</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Karin</surname> <given-names>M</given-names></name>. <article-title>Inflammation meets cancer, with NF-kappaB as the matchmaker</article-title>. <source>Nature immunology</source>. <year>2011</year>;<volume>12</volume>(<issue>8</issue>):<fpage>715</fpage>–<lpage>23</lpage>. Epub 2011/07/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2060" xlink:type="simple">10.1038/ni.2060</ext-link></comment> <object-id pub-id-type="pmid">21772280</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sovak</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Bellas</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Zanieski</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Rogers</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Traish</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer</article-title>. <source>The Journal of clinical investigation</source>. <year>1997</year>;<volume>100</volume>(<issue>12</issue>):<fpage>2952</fpage>–<lpage>60</lpage>. Epub 1998/01/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI119848" xlink:type="simple">10.1172/JCI119848</ext-link></comment> <object-id pub-id-type="pmid">9399940</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nair</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Venkatraman</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Maliekal</surname> <given-names>TT</given-names></name>, <name name-style="western"><surname>Nair</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Karunagaran</surname> <given-names>D</given-names></name>. <article-title>NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix</article-title>. <source>Oncogene</source>. <year>2003</year>;<volume>22</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>8</lpage>. Epub 2003/01/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1206043" xlink:type="simple">10.1038/sj.onc.1206043</ext-link></comment> <object-id pub-id-type="pmid">12527907</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gilmore</surname> <given-names>TD</given-names></name>. <article-title>Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel</article-title>. <source>Oncogene</source>. <year>1999</year>;<volume>18</volume>(<issue>49</issue>):<fpage>6925</fpage>–<lpage>37</lpage>. Epub 1999/12/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1203222" xlink:type="simple">10.1038/sj.onc.1203222</ext-link></comment> <object-id pub-id-type="pmid">10602467</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gilmore</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Cormier</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jean-Jacques</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gapuzan</surname> <given-names>ME</given-names></name>. <article-title>Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel</article-title>. <source>Oncogene</source>. <year>2001</year>;<volume>20</volume>(<issue>48</issue>):<fpage>7098</fpage>–<lpage>103</lpage>. Epub 2001/11/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1204898" xlink:type="simple">10.1038/sj.onc.1204898</ext-link></comment> <object-id pub-id-type="pmid">11704834</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gilmore</surname> <given-names>TD</given-names></name>, <name name-style="western"><surname>Kalaitzidis</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Liang</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Starczynowski</surname> <given-names>DT</given-names></name>. <article-title>The c-Rel transcription factor and B-cell proliferation: a deal with the devil</article-title>. <source>Oncogene</source>. <year>2004</year>;<volume>23</volume>(<issue>13</issue>):<fpage>2275</fpage>–<lpage>86</lpage>. Epub 2004/02/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1207410" xlink:type="simple">10.1038/sj.onc.1207410</ext-link></comment> <object-id pub-id-type="pmid">14755244</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenwald</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wright</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>WC</given-names></name>, <name name-style="western"><surname>Connors</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Campo</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Fisher</surname> <given-names>RI</given-names></name>, <etal>et al</etal>. <article-title>The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma</article-title>. <source>The New England journal of medicine</source>. <year>2002</year>;<volume>346</volume>(<issue>25</issue>):<fpage>1937</fpage>–<lpage>47</lpage>. Epub 2002/06/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa012914" xlink:type="simple">10.1056/NEJMoa012914</ext-link></comment> <object-id pub-id-type="pmid">12075054</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Houldsworth</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Olshen</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Cattoretti</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Donnelly</surname> <given-names>GB</given-names></name>, <name name-style="western"><surname>Teruya-Feldstein</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Qin</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas</article-title>. <source>Blood</source>. <year>2004</year>;<volume>103</volume>(<issue>5</issue>):<fpage>1862</fpage>–<lpage>8</lpage>. Epub 2003/11/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2003-04-1359" xlink:type="simple">10.1182/blood-2003-04-1359</ext-link></comment> <object-id pub-id-type="pmid">14615382</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shehata</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shehata</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Pater</surname> <given-names>A</given-names></name>. <article-title>Apoptosis effects of Xrel3 c-Rel/Nuclear Factor-kappa B homolog in human cervical cancer cells</article-title>. <source>Cell biology international</source>. <year>2005</year>;<volume>29</volume>(<issue>6</issue>):<fpage>429</fpage>–<lpage>40</lpage>. Epub 2005/08/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cellbi.2004.12.014" xlink:type="simple">10.1016/j.cellbi.2004.12.014</ext-link></comment> <object-id pub-id-type="pmid">16054560</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lorenz</surname> <given-names>VN</given-names></name>, <name name-style="western"><surname>Schon</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Seitz</surname> <given-names>CS</given-names></name>. <article-title>c-Rel downregulation affects cell cycle progression of human keratinocytes</article-title>. <source>The Journal of investigative dermatology</source>. <year>2014</year>;<volume>134</volume>(<issue>2</issue>):<fpage>415</fpage>–<lpage>22</lpage>. Epub 2013/07/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/jid.2013.315" xlink:type="simple">10.1038/jid.2013.315</ext-link></comment> <object-id pub-id-type="pmid">23892589</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shehata</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shehata</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Pater</surname> <given-names>A</given-names></name>. <article-title>Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells</article-title>. <source>Cell biology international</source>. <year>2004</year>;<volume>28</volume>(<issue>12</issue>):<fpage>895</fpage>–<lpage>904</lpage>. Epub 2004/11/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cellbi.2004.09.002" xlink:type="simple">10.1016/j.cellbi.2004.09.002</ext-link></comment> <object-id pub-id-type="pmid">15566959</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Horvath</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Barrangou</surname> <given-names>R</given-names></name>. <article-title>CRISPR/Cas, the immune system of bacteria and archaea</article-title>. <source>Science</source>. <year>2010</year>;<volume>327</volume>(<issue>5962</issue>):<fpage>167</fpage>–<lpage>70</lpage>. Epub 2010/01/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1179555" xlink:type="simple">10.1126/science.1179555</ext-link></comment> <object-id pub-id-type="pmid">20056882</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cong</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ran</surname> <given-names>FA</given-names></name>, <name name-style="western"><surname>Cox</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Barretto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Habib</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title>. <source>Science</source>. <year>2013</year>;<volume>339</volume>(<issue>6121</issue>):<fpage>819</fpage>–<lpage>23</lpage>. Epub 2013/01/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1231143" xlink:type="simple">10.1126/science.1231143</ext-link></comment> <object-id pub-id-type="pmid">23287718</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mali</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Esvelt</surname> <given-names>KM</given-names></name>, <name name-style="western"><surname>Aach</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Guell</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>DiCarlo</surname> <given-names>JE</given-names></name>, <etal>et al</etal>. <article-title>RNA-guided human genome engineering via Cas9</article-title>. <source>Science</source>. <year>2013</year>;<volume>339</volume>(<issue>6121</issue>):<fpage>823</fpage>–<lpage>6</lpage>. Epub 2013/01/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1232033" xlink:type="simple">10.1126/science.1232033</ext-link></comment> <object-id pub-id-type="pmid">23287722</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matano</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Date</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Shimokawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Takano</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fujii</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ohta</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids</article-title>. <source>Nature medicine</source>. <year>2015</year>;<volume>21</volume>(<issue>3</issue>):<fpage>256</fpage>–<lpage>62</lpage>. Epub 2015/02/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.3802" xlink:type="simple">10.1038/nm.3802</ext-link></comment> <object-id pub-id-type="pmid">25706875</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jinek</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>East</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Doudna</surname> <given-names>J</given-names></name>. <article-title>RNA-programmed genome editing in human cells</article-title>. <source>eLife</source>. <year>2013</year>;<volume>2</volume>:<fpage>e00471</fpage>. Epub 2013/02/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7554/eLife.00471" xlink:type="simple">10.7554/eLife.00471</ext-link></comment> <object-id pub-id-type="pmid">23386978</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ran</surname> <given-names>FA</given-names></name>, <name name-style="western"><surname>Hsu</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Gootenberg</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Konermann</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Trevino</surname> <given-names>AE</given-names></name>, <etal>et al</etal>. <article-title>Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity</article-title>. <source>Cell</source>. <year>2013</year>;<volume>154</volume>(<issue>6</issue>):<fpage>1380</fpage>–<lpage>9</lpage>. Epub 2013/09/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2013.08.021" xlink:type="simple">10.1016/j.cell.2013.08.021</ext-link></comment> <object-id pub-id-type="pmid">23992846</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sakuma</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nishikawa</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kume</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chayama</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>T</given-names></name>. <article-title>Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system</article-title>. <source>Scientific reports</source>. <year>2014</year>;<volume>4</volume>:<fpage>5400</fpage>. Epub 2014/06/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep05400" xlink:type="simple">10.1038/srep05400</ext-link></comment> <object-id pub-id-type="pmid">24954249</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neumann</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Walter</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Heriche</surname> <given-names>JK</given-names></name>, <name name-style="western"><surname>Bulkescher</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Erfle</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Conrad</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes</article-title>. <source>Nature</source>. <year>2010</year>;<volume>464</volume>(<issue>7289</issue>):<fpage>721</fpage>–<lpage>7</lpage>. Epub 2010/04/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature08869" xlink:type="simple">10.1038/nature08869</ext-link></comment> <object-id pub-id-type="pmid">20360735</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tokunaga</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stegeman</surname> <given-names>JJ</given-names></name>. <article-title>Elimination of nonspecific bands in non-radioactive electrophoretic mobility shift assays using the digoxigenin system</article-title>. <source>Analytical biochemistry</source>. <year>2014</year>;<volume>465</volume>:<fpage>70</fpage>–<lpage>2</lpage>. Epub 2014/07/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ab.2014.06.020" xlink:type="simple">10.1016/j.ab.2014.06.020</ext-link></comment> <object-id pub-id-type="pmid">25004462</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaltschmidt</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kaltschmidt</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hehner</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Droge</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Schmitz</surname> <given-names>ML</given-names></name>. <article-title>Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators</article-title>. <source>Oncogene</source>. <year>1999</year>;<volume>18</volume>(<issue>21</issue>):<fpage>3213</fpage>–<lpage>25</lpage>. Epub 1999/06/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1202657" xlink:type="simple">10.1038/sj.onc.1202657</ext-link></comment> <object-id pub-id-type="pmid">10359527</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forbes</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Beare</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Gunasekaran</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Bindal</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Boutselakis</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title>. <source>Nucleic acids research</source>. <year>2015</year>;<volume>43</volume>(<issue>Database issue</issue>):<fpage>D805</fpage>–<lpage>11</lpage>. Epub 2014/10/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gku1075" xlink:type="simple">10.1093/nar/gku1075</ext-link></comment> <object-id pub-id-type="pmid">25355519</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stemmer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Thumberger</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Del Sol Keyer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Wittbrodt</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mateo</surname> <given-names>JL</given-names></name>. <article-title>CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool</article-title>. <source>PloS one</source>. <year>2015</year>;<volume>10</volume>(<issue>4</issue>):<fpage>e0124633</fpage>. Epub 2015/04/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0124633" xlink:type="simple">10.1371/journal.pone.0124633</ext-link></comment> <object-id pub-id-type="pmid">25909470</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ouyang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Three-dimensional printing of Hela cells for cervical tumor model in vitro</article-title>. <source>Biofabrication</source>. <year>2014</year>;<volume>6</volume>(<issue>3</issue>):<fpage>035001</fpage>. Epub 2014/04/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1088/1758-5082/6/3/035001" xlink:type="simple">10.1088/1758-5082/6/3/035001</ext-link></comment> <object-id pub-id-type="pmid">24722236</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vidya Priyadarsini</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Senthil Murugan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Maitreyi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ramalingam</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Karunagaran</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Nagini</surname> <given-names>S</given-names></name>. <article-title>The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kappaB inhibition</article-title>. <source>European journal of pharmacology</source>. <year>2010</year>;<volume>649</volume>(<issue>1–3</issue>):<fpage>84</fpage>–<lpage>91</lpage>. Epub 2010/09/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejphar.2010.09.020" xlink:type="simple">10.1016/j.ejphar.2010.09.020</ext-link></comment> <object-id pub-id-type="pmid">20858478</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hamada</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Alemany</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>WW</given-names></name>, <name name-style="western"><surname>Hittelman</surname> <given-names>WN</given-names></name>, <name name-style="western"><surname>Lotan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Roth</surname> <given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer</article-title>. <source>Cancer research</source>. <year>1996</year>;<volume>56</volume>(<issue>13</issue>):<fpage>3047</fpage>–<lpage>54</lpage>. Epub 1996/07/01. <object-id pub-id-type="pmid">8674061</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref040"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Gilmore TD. NF-kB Target Genes. <ext-link ext-link-type="uri" xlink:href="https://www.bu.edu/nf-kb/gene-resources/target-genes/" xlink:type="simple">https://www.bu.edu/nf-kb/gene-resources/target-genes/</ext-link>: Boston University Biology; [cited 2017 13.02.].</mixed-citation></ref>
<ref id="pone.0182373.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buss</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Dorrie</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schmitz</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Hoffmann</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Resch</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kracht</surname> <given-names>M</given-names></name>. <article-title>Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription</article-title>. <source>The Journal of biological chemistry</source>. <year>2004</year>;<volume>279</volume>(<issue>53</issue>):<fpage>55633</fpage>–<lpage>43</lpage>. Epub 2004/10/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M409825200" xlink:type="simple">10.1074/jbc.M409825200</ext-link></comment> <object-id pub-id-type="pmid">15489227</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harris</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Oliere</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Hiscott</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>177</volume>(<issue>4</issue>):<fpage>2527</fpage>–<lpage>35</lpage>. Epub 2006/08/05. <object-id pub-id-type="pmid">16888014</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eddy</surname> <given-names>SF</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Demicco</surname> <given-names>EG</given-names></name>, <name name-style="western"><surname>Romieu-Mourez</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Landesman-Bollag</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Seldin</surname> <given-names>DC</given-names></name>, <etal>et al</etal>. <article-title>Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells</article-title>. <source>Cancer research</source>. <year>2005</year>;<volume>65</volume>(<issue>24</issue>):<fpage>11375</fpage>–<lpage>83</lpage>. Epub 2005/12/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-05-1602" xlink:type="simple">10.1158/0008-5472.CAN-05-1602</ext-link></comment> <object-id pub-id-type="pmid">16357145</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grumont</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lock</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Mollinari</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shannon</surname> <given-names>FM</given-names></name>, <name name-style="western"><surname>Moore</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gerondakis</surname> <given-names>S</given-names></name>. <article-title>The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression</article-title>. <source>Immunity</source>. <year>2004</year>;<volume>21</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>30</lpage>. Epub 2004/09/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.immuni.2004.06.004" xlink:type="simple">10.1016/j.immuni.2004.06.004</ext-link></comment> <object-id pub-id-type="pmid">15345217</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grey</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Arvelo</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Hasenkamp</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Bach</surname> <given-names>FH</given-names></name>, <name name-style="western"><surname>Ferran</surname> <given-names>C</given-names></name>. <article-title>A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets</article-title>. <source>The Journal of experimental medicine</source>. <year>1999</year>;<volume>190</volume>(<issue>8</issue>):<fpage>1135</fpage>–<lpage>46</lpage>. Epub 1999/10/19. <object-id pub-id-type="pmid">10523611</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boise</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Gonzalez-Garcia</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Postema</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lindsten</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Turka</surname> <given-names>LA</given-names></name>, <etal>et al</etal>. <article-title>bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death</article-title>. <source>Cell</source>. <year>1993</year>;<volume>74</volume>(<issue>4</issue>):<fpage>597</fpage>–<lpage>608</lpage>. Epub 1993/08/27. <object-id pub-id-type="pmid">8358789</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grossmann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>O'Reilly</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Gugasyan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Strasser</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Adams</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Gerondakis</surname> <given-names>S</given-names></name>. <article-title>The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression</article-title>. <source>The EMBO journal</source>. <year>2000</year>;<volume>19</volume>(<issue>23</issue>):<fpage>6351</fpage>–<lpage>60</lpage>. Epub 2000/12/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/emboj/19.23.6351" xlink:type="simple">10.1093/emboj/19.23.6351</ext-link></comment> <object-id pub-id-type="pmid">11101508</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Edelstein</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Gelinas</surname> <given-names>C</given-names></name>. <article-title>The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L)</article-title>. <source>Molecular and cellular biology</source>. <year>2000</year>;<volume>20</volume>(<issue>8</issue>):<fpage>2687</fpage>–<lpage>95</lpage>. Epub 2000/03/25. <object-id pub-id-type="pmid">10733571</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Siervi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>De Luca</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Moiola</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gueron</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Tongbai</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Chandramouli</surname> <given-names>GV</given-names></name>, <etal>et al</etal>. <article-title>Identification of new Rel/NFkappaB regulatory networks by focused genome location analysis</article-title>. <source>Cell Cycle</source>. <year>2009</year>;<volume>8</volume>(<issue>13</issue>):<fpage>2093</fpage>–<lpage>100</lpage>. Epub 2009/06/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/cc.8.13.8926" xlink:type="simple">10.4161/cc.8.13.8926</ext-link></comment> <object-id pub-id-type="pmid">19502793</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Strutz</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Zeisberg</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Renziehausen</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Raschke</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Becker</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>van Kooten</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2)</article-title>. <source>Kidney international</source>. <year>2001</year>;<volume>59</volume>(<issue>2</issue>):<fpage>579</fpage>–<lpage>92</lpage>. Epub 2001/02/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1046/j.1523-1755.2001.059002579.x" xlink:type="simple">10.1046/j.1523-1755.2001.059002579.x</ext-link></comment> <object-id pub-id-type="pmid">11168939</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Adli</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Baldwin</surname> <given-names>AS</given-names></name>. <article-title>IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation</article-title>. <source>The Journal of biological chemistry</source>. <year>2006</year>;<volume>281</volume>(<issue>37</issue>):<fpage>26976</fpage>–<lpage>84</lpage>. Epub 2006/07/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M603133200" xlink:type="simple">10.1074/jbc.M603133200</ext-link></comment> <object-id pub-id-type="pmid">16840782</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tian</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Liou</surname> <given-names>HC</given-names></name>. <article-title>RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo</article-title>. <source>PloS one</source>. <year>2009</year>;<volume>4</volume>(<issue>4</issue>):<fpage>e5028</fpage>. Epub 2009/04/07. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0005028" xlink:type="simple">10.1371/journal.pone.0005028</ext-link></comment> <object-id pub-id-type="pmid">19347041</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grumont</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Rourke</surname> <given-names>IJ</given-names></name>, <name name-style="western"><surname>O'Reilly</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Strasser</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Miyake</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sha</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells</article-title>. <source>The Journal of experimental medicine</source>. <year>1998</year>;<volume>187</volume>(<issue>5</issue>):<fpage>663</fpage>–<lpage>74</lpage>. Epub 1998/03/28. <object-id pub-id-type="pmid">9480976</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosette</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Roth</surname> <given-names>RB</given-names></name>, <name name-style="western"><surname>Oeth</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Braun</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kammerer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ekblom</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Role of ICAM1 in invasion of human breast cancer cells</article-title>. <source>Carcinogenesis</source>. <year>2005</year>;<volume>26</volume>(<issue>5</issue>):<fpage>943</fpage>–<lpage>50</lpage>. Epub 2005/03/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/carcin/bgi070" xlink:type="simple">10.1093/carcin/bgi070</ext-link></comment> <object-id pub-id-type="pmid">15774488</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Soucek</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Whitfield</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Sodir</surname> <given-names>NM</given-names></name>, <name name-style="western"><surname>Masso-Valles</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Serrano</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Karnezis</surname> <given-names>AN</given-names></name>, <etal>et al</etal>. <article-title>Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice</article-title>. <source>Genes &amp; development</source>. <year>2013</year>;<volume>27</volume>(<issue>5</issue>):<fpage>504</fpage>–<lpage>13</lpage>. Epub 2013/03/12.</mixed-citation></ref>
<ref id="pone.0182373.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Krappmann</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Emmerich</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Kordes</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Scharschmidt</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Dorken</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Scheidereit</surname> <given-names>C</given-names></name>. <article-title>Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells</article-title>. <source>Oncogene</source>. <year>1999</year>;<volume>18</volume>(<issue>4</issue>):<fpage>943</fpage>–<lpage>53</lpage>. Epub 1999/02/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.onc.1202351" xlink:type="simple">10.1038/sj.onc.1202351</ext-link></comment> <object-id pub-id-type="pmid">10023670</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perkins</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Gilmore</surname> <given-names>TD</given-names></name>. <article-title>Good cop, bad cop: the different faces of NF-kappaB</article-title>. <source>Cell death and differentiation</source>. <year>2006</year>;<volume>13</volume>(<issue>5</issue>):<fpage>759</fpage>–<lpage>72</lpage>. Epub 2006/01/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.cdd.4401838" xlink:type="simple">10.1038/sj.cdd.4401838</ext-link></comment> <object-id pub-id-type="pmid">16410803</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref058"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Forbes SA. cancer.sanger.ac.uk [cited 2017 14.02].</mixed-citation></ref>
<ref id="pone.0182373.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Futreal</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Coin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Marshall</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Down</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hubbard</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Wooster</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>A census of human cancer genes</article-title>. <source>Nature reviews Cancer</source>. <year>2004</year>;<volume>4</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>83</lpage>. Epub 2004/03/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrc1299" xlink:type="simple">10.1038/nrc1299</ext-link></comment> <object-id pub-id-type="pmid">14993899</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wilhelmsen</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Eggleton</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Temin</surname> <given-names>HM</given-names></name>. <article-title>Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogene c-rel</article-title>. <source>Journal of virology</source>. <year>1984</year>;<volume>52</volume>(<issue>1</issue>):<fpage>172</fpage>–<lpage>82</lpage>. Epub 1984/10/01. <object-id pub-id-type="pmid">6090694</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Lippard</surname> <given-names>SJ</given-names></name>. <article-title>Cellular processing of platinum anticancer drugs</article-title>. <source>Nature reviews Drug discovery</source>. <year>2005</year>;<volume>4</volume>(<issue>4</issue>):<fpage>307</fpage>–<lpage>20</lpage>. Epub 2005/03/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrd1691" xlink:type="simple">10.1038/nrd1691</ext-link></comment> <object-id pub-id-type="pmid">15789122</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peters</surname> <given-names>GJ</given-names></name>, <name name-style="western"><surname>Backus</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Freemantle</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>van Triest</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Codacci-Pisanelli</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>van der Wilt</surname> <given-names>CL</given-names></name>, <etal>et al</etal>. <article-title>Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism</article-title>. <source>Biochimica et biophysica acta</source>. <year>2002</year>;<volume>1587</volume>(<issue>2–3</issue>):<fpage>194</fpage>–<lpage>205</lpage>. Epub 2002/06/27. <object-id pub-id-type="pmid">12084461</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Cusack</surname> <given-names>JC</given-names> <suffix>Jr.</suffix></name>, <name name-style="western"><surname>Liu</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Baldwin</surname> <given-names>AS</given-names> <suffix>Jr.</suffix></name>. <article-title>Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB</article-title>. <source>Nature medicine</source>. <year>1999</year>;<volume>5</volume>(<issue>4</issue>):<fpage>412</fpage>–<lpage>7</lpage>. Epub 1999/04/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/7410" xlink:type="simple">10.1038/7410</ext-link></comment> <object-id pub-id-type="pmid">10202930</object-id></mixed-citation></ref>
<ref id="pone.0182373.ref064"><label>64</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Mutations of p53 and KRAS activate NF-kappaB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells</article-title>. <source>Cancer letters</source>. <year>2015</year>;<volume>357</volume>(<issue>2</issue>):<fpage>520</fpage>–<lpage>6</lpage>. Epub 2014/12/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.canlet.2014.12.003" xlink:type="simple">10.1016/j.canlet.2014.12.003</ext-link></comment> <object-id pub-id-type="pmid">25499080</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>